Waters Co. (NYSE:WAT) Shares Sold by Nuance Investments LLC

Nuance Investments LLC lowered its position in Waters Co. (NYSE:WAT) by 32.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 58,223 shares of the medical instruments supplier’s stock after selling 27,692 shares during the period. Nuance Investments LLC owned approximately 0.10% of Waters worth $20,953,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Itau Unibanco Holding S.A. purchased a new stake in shares of Waters in the 2nd quarter valued at $33,000. Kennebec Savings Bank purchased a new stake in Waters in the third quarter valued at $33,000. Blue Trust Inc. grew its position in Waters by 190.2% during the 2nd quarter. Blue Trust Inc. now owns 119 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 78 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Waters during the 3rd quarter worth about $35,000. Finally, TFC Financial Management Inc. raised its stake in shares of Waters by 19,900.0% during the 2nd quarter. TFC Financial Management Inc. now owns 200 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 199 shares during the last quarter. 94.01% of the stock is owned by hedge funds and other institutional investors.

Waters Trading Down 3.0 %

Shares of WAT stock opened at $344.80 on Wednesday. Waters Co. has a fifty-two week low of $258.89 and a fifty-two week high of $393.38. The firm has a market capitalization of $20.47 billion, a P/E ratio of 32.90, a PEG ratio of 6.50 and a beta of 0.97. The stock’s fifty day moving average is $351.55 and its two-hundred day moving average is $331.13. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.38 and a current ratio of 2.02.

Waters (NYSE:WAT) last posted its quarterly earnings results on Friday, November 1st. The medical instruments supplier reported $2.93 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.25. The firm had revenue of $740.30 million for the quarter, compared to analyst estimates of $712.99 million. Waters had a net margin of 21.43% and a return on equity of 49.93%. Waters’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.84 earnings per share. Research analysts expect that Waters Co. will post 11.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Evercore ISI upped their target price on Waters from $335.00 to $355.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. TD Cowen raised their price objective on shares of Waters from $363.00 to $410.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Wells Fargo & Company boosted their target price on shares of Waters from $380.00 to $415.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Barclays raised their price target on shares of Waters from $330.00 to $360.00 and gave the company an “underweight” rating in a research report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on shares of Waters from $310.00 to $325.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $365.85.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.